Status:
TERMINATED
ESKETamine for FIBromyalgia Treatment
Lead Sponsor:
Grand Hôpital de Charleroi
Conditions:
Fibromyalgia
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Fibromyalgia is a cause of chronic pain, classified by the Internal Classification of Diseases (ICD) as a primary chronic pain with specific diagnostic criteria established by the American College of ...
Detailed Description
Ketamine is a drug used for anesthesia since the 1970s, acting as an antagonist to the N-methyl-D-aspartate receptor located in the central nervous system. It has two stereoisomers : R +ketamine and S...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- patients suffering from chronic pain (as defined by International Association for the Study of Pain) being diagnosed as fibromyalgia according to the American College of Rheumatology 2016 criteria
- patients qualified for the treatment by S-ketamine as established by our latest clinical practice
- patients aged 18-65 years old
Exclusion
Key Trial Info
Start Date :
October 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT04436250
Start Date
October 10 2020
End Date
September 30 2024
Last Update
November 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Grand Hôpital de Charleroi
Gilly, Hainaut, Belgium, 6060